These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34722810)

  • 1. Proton Therapy of Prostate and Pelvic Lymph Nodes for High Risk Prostate Cancer: Acute Toxicity.
    Choo R; Hillman DW; Daniels T; Vargas C; Rwigema JC; Corbin K; Keole S; Vora S; Merrell K; Stish B; Pisansky T; Davis B; Amundson A; Wong W
    Int J Part Ther; 2021; 8(2):41-50. PubMed ID: 34722810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late Toxicity of Moderately Hypofractionated Intensity-Modulated Proton Therapy Treating the Prostate and Pelvic Lymph Nodes for High-Risk Prostate Cancer.
    Choo R; Hillman DW; Mitchell C; Daniels T; Vargas C; Rwigema JC; Corbin K; Keole S; Vora S; Merrell K; Stish B; Pisansky T; Davis BJ; Amundson A; Wong W
    Int J Radiat Oncol Biol Phys; 2023 Apr; 115(5):1085-1094. PubMed ID: 36427645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
    Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
    Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study.
    Jorgo K; Polgar C; Major T; Stelczer G; Herein A; Pocza T; Gesztesi L; Agoston P
    Pathol Oncol Res; 2020 Apr; 26(2):905-912. PubMed ID: 30888646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1/2 study of hypofractionated intensity-modulated radiation therapy for prostate cancer including simultaneously integrated boost.
    Chang MG; Mukhopadhyay N; Holdford D; Skinner V; Saraiya S; Moghanaki D; Anscher MS
    Pract Radiat Oncol; 2018; 8(3):e149-e157. PubMed ID: 29290572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
    Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Tolerance Outcomes of Stereotactic Hypofractionated Accelerated Radiation Therapy Concomitant with Pelvic Node Irradiation in High-risk Prostate Cancer.
    Pinitpatcharalert A; Happersett L; Kollmeier M; McBride S; Gorovets D; Tyagi N; Varghese M; Zelefsky MJ
    Adv Radiat Oncol; 2019; 4(2):337-344. PubMed ID: 31011679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer.
    Lock M; Best L; Wong E; Bauman G; D'Souza D; Venkatesan V; Sexton T; Ahmad B; Izawa J; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1306-15. PubMed ID: 20708855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost.
    Phuong C; Chan JW; Ni L; Wall P; Mohamad O; Wong AC; Hsu IC; Chang AJ
    Radiat Oncol; 2022 Jan; 17(1):12. PubMed ID: 35057827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy.
    Faria S; Ruo R; Cury F; Duclos M; Souhami L
    Pract Radiat Oncol; 2017; 7(4):264-269. PubMed ID: 28222995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
    Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for patients with prostate-specific antigen relapse or local recurrence after radical prostatectomy.
    Pearse M; Choo R; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw A; Cheung P
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):792-8. PubMed ID: 18707818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moderately Hypofractionated Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Prostate Cancer: Five-Year Toxicity Results From a Prospective Phase I/II Trial.
    Ricco A; Mukhopadhyay N; Deng X; Holdford D; Skinner V; Saraiya S; Moghanaki D; Anscher MS; Chang MG
    Front Oncol; 2020; 10():1686. PubMed ID: 32974208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
    Leite ETT; Ramos CCA; Ribeiro VAB; Salvajoli BP; Nahas WC; Salvajoli JV; Ynoe Moraes F
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1263-1270. PubMed ID: 33346091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review.
    Matta R; Chapple CR; Fisch M; Heidenreich A; Herschorn S; Kodama RT; Koontz BF; Murphy DG; Nguyen PL; Nam RK
    Eur Urol; 2019 Mar; 75(3):464-476. PubMed ID: 30573316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extreme hypofractionated proton radiotherapy for prostate cancer using pencil beam scanning: Dosimetry, acute toxicity and preliminary results.
    Kubeš J; Vondráček V; Andrlik M; Navrátil M; Sláviková S; Vítek P; Rosina J; Abrahámová J; Prausová J; Grebenyuk A; Dědečková K
    J Med Imaging Radiat Oncol; 2019 Dec; 63(6):829-835. PubMed ID: 31486267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity.
    Fersino S; Tebano U; Mazzola R; Giaj-Levra N; Ricchetti F; Di Paola G; Fiorentino A; Sicignano G; Naccarato S; Ruggieri R; Cavalleri S; Alongi F
    Clin Genitourin Cancer; 2017 Aug; 15(4):e667-e673. PubMed ID: 28237181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity After Stereotactic Body Radiation Therapy for Prostate Cancer in Patients With Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control Series.
    Juarez JE; Romero T; Mantz CA; Pepin A; Aghdam N; Suy S; Steinberg ML; Levin-Epstein RG; Nickols NG; Kaplan ID; Meier RM; Pham HT; Linson PW; Hong RL; Buyyounouski MK; Bagshaw HP; Fuller DB; Katz AJ; Loblaw A; Collins SP; Kishan AU
    Adv Radiat Oncol; 2021; 6(6):100759. PubMed ID: 34585025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.
    Adkison JB; McHaffie DR; Bentzen SM; Patel RR; Khuntia D; Petereit DG; Hong TS; Tomé W; Ritter MA
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):184-90. PubMed ID: 21163590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.